Population pharmacokinetic analyses of regorafenib and capecitabine in patients with locally advanced rectal cancer (SAKK 41/16 RECAP).

Publikation

Population pharmacokinetic analyses of regorafenib and capecitabine in patients with locally advanced rectal cancer (SAKK 41/16 RECAP).

Wissenschaftlicher Artikel/Review - 23.07.2022

Schmulenson Eduard, Bovet Cédric, Theurillat Regula, Decosterd Laurent Arthur, Largiadèr Carlo R, Prost Jean-Christophe, Csajka Chantal, Bärtschi Daniela, Guckenberger Matthias, von Moos Roger, Bastian Sara, Jörger Markus, Jaehde Ulrich

Zitation

Schmulenson E, Bovet C, Theurillat R, Decosterd L, Largiadèr C, Prost J, Csajka C, Bärtschi D, Guckenberger M, von Moos R, Bastian S, Jörger M, Jaehde U. Population pharmacokinetic analyses of regorafenib and capecitabine in patients with locally advanced rectal cancer (SAKK 41/16 RECAP). Br J Clin Pharmacol 2022; 88:5336-5347.

Art

Wissenschaftlicher Artikel/Review (Englisch)

Zeitschrift

Br J Clin Pharmacol 2022; 88

Veröffentlichungsdatum

23.07.2022

eISSN (Online)

1365-2125

Seiten

5336-5347

Kurzbeschreibung/Zielsetzung

Locally advanced rectal cancer (LARC) is an area of unmet medical need with one third of patients dying from their disease. With response to neoadjuvant chemo-radiotherapy being a major prognostic factor, trial SAKK 41/16 assessed potential benefits of adding regorafenib to capecitabine-amplified neoadjuvant radiotherapy in LARC patients.